Targeting HIV-1 gag into the defective ribosomal product pathway enhances MHC class I antigen presentation and CD8+ T cell activation

Journal of Immunology

Volumn 180, Issue 1, 2008, Pages 372-382

  Goldwich, Andreas ^a   Hahn, Sabine S C ^a   Schreiber, Sandra ^a   Meier, Stefanie ^a   Kämpgen, Eckhart ^a   Wagner, Ralf ^b   Lutz, Manfred B ^c   Schubert, Ulrich ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; UBIQUITIN; HLA ANTIGEN CLASS 1; PEPTIDE; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; C57BL 6 MOUSE; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CELL LINE; CELL STIMULATION; CELL STRAIN B3Z; CELL STRAIN EL4; CELL STRAIN OT 1; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYBRIDOMA CELL CULTURE; IMMUNIZATION; IN VITRO SELECTION; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; RIBOSOME; T LYMPHOCYTE ACTIVATION; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENETICS; HYBRIDOMA; IMMUNOLOGY; METABOLISM; MOUSE; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV-1; HUMANS; HYBRIDOMAS; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDES; RIBOSOMES; T-LYMPHOCYTES, CYTOTOXIC; UBIQUITIN;

EID: 40449118398     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.1.372     Document Type: Article

References (76)

1. Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771.
2. Goldberg, A. L., and K. L. Rock. 1992. Proteolysis, proteasomes, and antigen presentation. Nature 357: 375-379.
3. Pamer, E., and P. Cresswell. 1998. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16: 323-358.
4. Kloetzel, P. M. 2004. The proteasome and MHC class I antigen processing. Biochim. Biophys. Acta 1695: 225-233.
5. Princiotta, M. F., D. Finzi, S. B. Qian, J. Gibbs, S. Schuchmann, F. Buttgereit, J. R. Bennink, and J. W. Yewdell. 2003. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18: 343-354.
6. Qian, S. B., E. Reits, J. Neefjes, J. M. Deslich, J. R. Bennink, and J. W. Yewdell. 2006. Tight linkage between translation and MHC class I peptide ligand generation implies specialized antigen processing for defective ribosomal products. J. Immunol. 177: 227-233.
7. Reits, E. A., J. C. Vos, M. Gromme, and J. Neefjes. 2000. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 404: 774-778.
8. Khan, S., R. de Giuli, G. Schmidtke, M. Bruns, M. Buchmeier, M. van den Broek, and M. Groettrup. 2001. Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J. Immunol. 167: 4801-4804.
9. Schubert, U., L. C. Anton, J. Gibbs, C. C. Norbury, J. W. Yewdell, and J. R. Bennink. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404: 770-774.
10. Yewdell, J. W., and C. V. Nicchitta. 2006. The DRiP hypothesis decennial: support, controversy, refinement, and extension. Trends Immunol. 27: 368-373.
11. Esquivel, F., J. Yewdell, and J. Bennink. 1992. RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J. Exp. Med. 175: 163-168.
12. Goldberg, A. L. 2003. Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899.
13. Varshavsky, A. 1991. Naming a targeting signal. Cell 64: 13-15.
14. Rechsteiner, M., and S. W. Rogers. 1996. PEST sequences and regulation by proteolysis. Trends Biochem. Sci. 21: 267-271.
15. Bachmair, A., D. Finley, and A. Varshavsky. 1986. In vivo half-life of a protein is a function of its amino-terminal residue. Science 234: 179-186.
16. Varshavsky, A. 1996. The N-end rule: functions, mysteries, uses. Proc. Natl. Acad. Sci. USA 93: 12142-12149.
17. Larsen, C. N., B. A. Krantz, and K. D. Wilkinson. 1998. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37: 3358-3368.
18. Johnson, E. S., P. C. Ma, I. M. Ota, and A. Varshavsky. 1995. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J. Biol. Chem. 270: 17442-17456.
19. Townsend, A., J. Bastin, K. Gould, G. Brownlee, M. Andrew, B. Coupar, D. Boyle, S. Chan, and G. Smith. 1988. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 168: 1211-1224.
20. Grant, E. P., M. T. Michalek, A. L. Goldberg, and K. L. Rock. 1995. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J. Immunol. 155: 3750-3758.
21. Sijts, A., D. Zaiss, and P. M. Kloetzel. 2001. The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. Curr. Mol. Med. 1: 665-676.
22. Villanueva, M. S., P. Fischer, K. Feen, and E. G. Pamer. 1994. Efficiency of MHC class I antigen processing: a quantitative analysis. Immunity 1: 479-489.
23. Wong, S. B., C. B. Buck, X. Shen, and R. F. Siliciano. 2004. An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses. J. Immunol. 173: 3073-3083.
24. Tobery, T., and R. F. Siliciano. 1999. Cutting edge: induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J. Immunol. 162: 639-642.
25. Goth, S., V. Nguyen, and N. Shastri. 1996. Generation of naturally processed peptide/MHC class I complexes is independent of the stability of endogenously synthesized precursors. J. Immunol. 157: 1894-1904.
26. Graf, M., A. Bojak, L. Deml, K. Bieler, H. Wolf, and R. Wagner. 2000. Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression. J. Virol. 74: 10822-10826.
27. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777-785.
28. Fossen, T., V. Wray, K. Bruns, J. Rachmat, P. Henklein, U. Tessmer, A. Maczurek, P. Klinger, and U. Schubert. 2005. Solution structure of the human immunodeficiency virus type 1 p6 protein. J. Biol. Chem. 280: 42515-42527.
29. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726.
30. d antibody. In The Immune System, Vol. 2. C. M. Steinberg and I. Lefkovits, eds. Karger, Basel. pp. 202-208.
31. Karttunen, J., and N. Shastri. 1991. Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene. Proc. Natl. Acad. Sci. USA 88: 3972-3976.
32. Sanderson, S., and N. Shastri. 1994. LacZ inducible, antigen/MHC-specific T cell hybrids. Int. Immunol. 6: 369-376.
33. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
34. HIV Sequence Compendium 2005.2005. T. F. Leitner, B. Hahn, P.Marx, F. McCutchan, J. W. Mellors, S. Wolinsky, and B. Korber, eds. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
35. Buck, C. B., X. Shen, M. A. Egan, T. C. Pierson, C. M. Walker, and R. F. Siliciano. 2001. The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site. J. Virol. 75: 181-191.
36. Lacaille, V. G., and M. J. Androlewicz. 2000. Targeting of HIV-1 Nef to the centrosome: implications for antigen processing. Traffic 1: 884-891.
37. Qian, S. B., J. R. Bennink, and J. W. Yewdell. 2005. Quantitating defective ribosome products. Methods Mol. Biol. 301: 271-281.
38. Fenteany, G., R. F. Standaert, W. S. Lane, S. Choi, E. J. Corey, and S. L. Schreiber. 1995. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268: 726-731.
39. Jager, S., E. Gottwein, and H. G. Krausslich. 2007. Ubiquitination of human immunodeficiency virus type 1 Gag is highly dependent on Gag membrane association. J. Virol. 81: 9193-9201.
40. Anton, L. C., H. L. Snyder, J. R. Bennink, A. Vinitsky, M. Orlowski, A. Porgador, and J. W. Yewdell. 1998. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J. Immunol. 160: 4859-4868.
41. Restifo, N. P., I. Bacik, K. R. Irvine, J. W. Yewdell, B. J. McCabe, R. W. Anderson, L. C. Eisenlohr, S. A. Rosenberg, and J. R. Bennink. 1995. Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 154: 4414-4422.
42. Storkus, W. J., H. J. Zeh, III, R. D. Salter, and M. T. Lotze. 1993. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J. Immunother. Emphasis Tumor Immunol. 14: 94-103.
43. + T lymphocytes. J. Exp. Med. 199: 459-470.
44. + T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J. Exp. Med. 199: 1421-1431.
45. Castilleja, A., N. E. Ward, C. A. O'Brian, B. Swearingen, Jr., E. Swan, M. A. Gillogly, J. L. Murray, A. P. Kudelka, D. M. Gershenson, and C. G. Ioannides. 2001. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL: implications for tumor immunogenicity. Mol. Cell. Biochem. 217: 21-33.
46. Karttunen, J., S. Sanderson, and N. Shastri. 1992. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci. USA 89: 6020-6024.
47. + T cells induced by major histocompatibility complex binding peptides in fetal thymic organ culture. J. Exp. Med. 177: 1469-1473.
48. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171: 131-137.
49. Draenert, R., C. L. Verrill, Y. Tang, T. M. Allen, A. G. Wurcel, M. Boczanowski, A. Lechner, A. Y. Kim, T. Suscovich, N. V. Brown, et al. 2004. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J. Virol. 78: 630-641.
50. Goulder, P. J., and D. I. Watkins. 2004. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 4: 630-640.
51. Letvin, N. L. 2005. Progress toward an HIV vaccine. Annu. Rev. Med. 56: 213-223.
52. Burton, D. R., R. C. Desrosiers, R. W. Doms, W. C. Koff, P. D. Kwong, J. P. Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, and R. T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5: 233-236.
53. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13: 46-53.
54. HIV Sequence Compendium 2005. T. F. Leitner, B. Hahn, P. Marx, F. McCutchan, J. W. Mellors, S. Wolinsky, and B. Korber, eds. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
55. Tobery, T. W., and R. F. Siliciano. 1997. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 185: 909-920.
56. de Groot, R. J., T. Rumenapf, R. J. Kuhn, E. G. Strauss, and J. H. Strauss. 1991. Sindbis virus RNA polymerase is degraded by the N-end rule pathway. Proc. Natl. Acad. Sci. USA 88: 8967-8971.
57. Fu, T. M., L. Guan, A. Friedman, J. B. Ulmer, M. A. Liu, and J. J. Donnelly. 1998. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens. Vaccine 16: 1711-1717.
58. Hoyt, M. A., and P. Coffino. 2004. Ubiquitin-free routes into the proteasome. Cell Mol. Life Sci. 61: 1596-1600.
59. Ostankovitch, M., V. Robila, and V. H. Engelhard. 2005. Regulated folding of tyrosinase in the endoplasmic reticulum demonstrates that misfolded full-length proteins are efficient substrates for class I processing and presentation. J. Immunol. 174: 2544-2551.
60. Golovina, T. N., S. E. Morrison, and L. C. Eisenlohr. 2005. The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing. J. Immunol. 174: 2763-2769.
61. + T cells. J. Immunol. 170: 1822-1829.
62. d-restricted cytotoxic T lymphocytes. J. Exp. Med. 173: 849-858.
63. Milligan, G. N., L. A. Morrison, J. Gorka, V. L. Braciale, and T. J. Braciale. 1990. The recognition of a viral antigenic moiety by class I MHC-restricted cytolytic T lymphocytes is limited by the availability of the endogenously processed antigen. J. Immunol. 145: 3188-3193.
64. Wherry, E. J., K. A. Puorro, A. Porgador, and L. C. Eisenlohr. 1999. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol. 163: 3735-3745.
65. Yewdell, J. W. 2007. Plumbing the sources of endogenous MHC class I peptide ligands. Curr. Opin. Immunol. 19: 79-86.
66. Bulik, S., B. Peters, and H. G. Holzhutter. 2005. Quantifying the contribution of defective ribosomal products to antigen production: a model-based computational analysis. J. Immunol. 175: 7957-7964.
67. Rodriguez, F., J. Zhang, and J. L. Whitton. 1997. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71: 8497-8503.
68. Wu, Y., and T. J. Kipps. 1997. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J. Immunol. 159: 6037-6043.
69. Rock, K. L., and L. Shen. 2005. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev. 207: 166-183.
70. Monu, N., and E. S. Trombetta. 2007. Cross-talk between the endocytic pathway and the endoplasmic reticulum in cross-presentation by MHC class I molecules. Curr. Opin. Immunol. 19: 66-72.
71. Ploegh, H. L. 2004. Immunology: nothing 'gainst time's scythe can make defense. Science 304: 1262-1263.
72. Shen, L., and K. L. Rock. 2006. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr. Opin. Immunol. 18: 85-91.
73. + T cell cross-priming via transfer of proteasome substrates. Science 304: 1318-1321.
74. Buseyne, F., S. Le Gall, C. Boccaccio, J. P. Abastado, J. D. Lifson, L. O. Arthur, Y. Riviere, J. M. Heard, and O. Schwartz. 2001. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat. Med. 7: 344-349.
75. Neijssen, J., C. Herberts, J. W. Drijfhout, E. Reits, L. Janssen, and J. Neefjes. 2005. Cross-presentation by intercellular peptide transfer through gap junctions. Nature 434: 83-88.
76. Sykulev, Y., M. Joo, I. Vturina, T. J. Tsomides, and H. N. Eisen. 1996. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4: 565-571.